ATE427758T1 - Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen - Google Patents

Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen

Info

Publication number
ATE427758T1
ATE427758T1 AT03735232T AT03735232T ATE427758T1 AT E427758 T1 ATE427758 T1 AT E427758T1 AT 03735232 T AT03735232 T AT 03735232T AT 03735232 T AT03735232 T AT 03735232T AT E427758 T1 ATE427758 T1 AT E427758T1
Authority
AT
Austria
Prior art keywords
reactions
inhibitor
inflammable
inhibit
chemotactic factor
Prior art date
Application number
AT03735232T
Other languages
English (en)
Inventor
Philippe Tessier
Carle Ryckman
Karen Vandal
Pascal Rouleau
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Application granted granted Critical
Publication of ATE427758T1 publication Critical patent/ATE427758T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03735232T 2002-07-05 2003-06-20 Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen ATE427758T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39352002P 2002-07-05 2002-07-05

Publications (1)

Publication Number Publication Date
ATE427758T1 true ATE427758T1 (de) 2009-04-15

Family

ID=30115596

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03735232T ATE427758T1 (de) 2002-07-05 2003-06-20 Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen

Country Status (7)

Country Link
US (4) US7553488B2 (de)
EP (1) EP1519749B1 (de)
AT (1) ATE427758T1 (de)
AU (1) AU2003236762A1 (de)
CA (1) CA2489860C (de)
DE (1) DE60327075D1 (de)
WO (1) WO2004004770A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608397B1 (de) * 2003-03-28 2008-10-15 Universite Laval S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
CA2573596A1 (en) * 2004-07-13 2006-01-19 Universite Laval S100 protein inhibitors for treating leukemia
WO2006122723A1 (en) * 2005-05-19 2006-11-23 Vaecgene Biotech Gmbh Method for the prevention and/or treatment of autoimmune disease or allogeneic transplant rejections
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5814549B2 (ja) * 2008-04-30 2015-11-17 株式会社ジェノミックス 損傷組織の機能的再生促進医薬
US8283131B2 (en) * 2008-10-28 2012-10-09 Assistance Publique-Hopitaux De Paris Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock
JP5865703B2 (ja) 2009-10-28 2016-02-17 株式会社ジェノミックス 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
RU2013123796A (ru) 2010-10-30 2014-12-10 Исис Инновэйшн Лтд Способ лечения болезни дюпюитрена
PT3358011T (pt) 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
WO2012155049A1 (en) * 2011-05-11 2012-11-15 Medimmune, Llc Treatment of lung inflammation
US9688733B2 (en) 2012-10-25 2017-06-27 Genomix Co., Ltd. Method for treating spinal cord injury using HMGB1 fragment
ES2660420T3 (es) 2012-10-25 2018-03-22 Genomix Co., Ltd. Método novedoso para tratar infarto cardiaco utilizando fragmento de HMGB1
US10005833B2 (en) * 2015-01-02 2018-06-26 Washington State University Methods of treating inflammation associated airway diseases and viral infections
US11359010B2 (en) * 2015-07-13 2022-06-14 UNIVERSITé LAVAL Humanized anti-S100A9 antibody and uses thereof
EP3349793B1 (de) * 2015-09-14 2021-08-11 Université Laval Anti-s100a8 zur behandlung von leukämie
EP3439701A4 (de) 2016-04-08 2019-12-11 180 Therapeutics LP Verfahren zur behandlung der dupuytren-krankheit im frühstadium
EP3556378B1 (de) 2017-01-27 2025-03-12 StemRIM Inc. Therapeutisches mittel für kardiomyopathie, alten myokardinfarkt und chronisches herzversagen
RU2757771C2 (ru) * 2017-02-07 2021-10-21 Люфстоун Ас Биомаркеры для диагностики связанного с имплантом риска повторной операции с имплантом из-за асептического расшатывания
WO2018209178A1 (en) 2017-05-11 2018-11-15 The Research Foundation For The State University Of New York Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid
CN111868231B (zh) 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
CN111542335A (zh) 2017-12-01 2020-08-14 斯特姆里姆有限公司 炎症性肠病的治疗药
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
WO2020051460A1 (en) * 2018-09-07 2020-03-12 Sanford Burnham Prebys Medical Discovery Institute Methods of diagnosis and treatment of inflammatory bowel disease
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052602T3 (es) * 1986-10-03 1994-07-16 Ciba Geigy Ag Nuevos peptidos afines a las linfocinas.
ATE228164T1 (de) * 1990-09-05 2002-12-15 Heart Res Inst Ltd Chemotaktische faktoren
US5248825A (en) * 1990-09-20 1993-09-28 Merrell Dow Pharmaceuticals Inc. Calcium uptake inhibitors
CA2280930C (en) * 1997-02-12 2010-04-06 The Regents Of The University Of Michigan Protein markers for lung cancer and use thereof
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
WO2000018970A1 (fr) * 1998-09-29 2000-04-06 Asahi Kasei Kabushiki Kaisha Procede de commande de liberation de granules
AU2002364607A1 (en) * 2001-12-28 2003-07-24 The Burnham Institute Novel ligand involved in the transmigration of leukocytes .
EP1608397B1 (de) * 2003-03-28 2008-10-15 Universite Laval S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
CA2573596A1 (en) * 2004-07-13 2006-01-19 Universite Laval S100 protein inhibitors for treating leukemia

Also Published As

Publication number Publication date
US20050288211A1 (en) 2005-12-29
AU2003236762A1 (en) 2004-01-23
EP1519749B1 (de) 2009-04-08
US20090275516A1 (en) 2009-11-05
EP1519749A1 (de) 2005-04-06
US20140348849A1 (en) 2014-11-27
US8282925B2 (en) 2012-10-09
WO2004004770A1 (en) 2004-01-15
CA2489860A1 (en) 2004-01-15
US7553488B2 (en) 2009-06-30
CA2489860C (en) 2015-02-10
DE60327075D1 (de) 2009-05-20
US20130273075A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
ATE427758T1 (de) Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen
EA200802285A1 (ru) Бивалентные миметики smac и их применения
MX2024009001A (es) Inhibidores de la pcsk9 y metodos de uso de los mismos.
BRPI0407195A (pt) inibidor de histona desacetilase, composição, e, método para inibir histona desacetilase em uma célula
WO2012178208A3 (en) Selective inhibitors of histone deacetylase isoform 6 and methods thereof
BRPI1013388A2 (pt) composição de limpeza que compreende uma alfa-amilase e uma protease e método de limpeza de um tecido ou superficie dura
EP3354640A3 (de) Mif-hemmer und verwendungen davon
GB2441727A (en) Corrosion inhibitor for acids
PL1660507T5 (pl) Inhibitory proteazomu oraz sposoby ich stosowania
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA200801784A1 (ru) Ингибиторы е1 активирующих ферментов
BR112012018246A2 (pt) compostos de amida reversa como inibidores de proteína desacetilase e métodos de uso destes
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
WO2005069888A3 (en) Smac peptidomimetics and the uses thereof
MX2009006542A (es) Inhibidores de histona desacetilasa y sus profarmacos.
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
MX375059B (es) Compuestos para el tratamiento de cancer.
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
NO20081636L (no) FAP - inhibitorer
EA201790882A1 (ru) Способы и композиции для терапии рака печени
EA201390270A1 (ru) Применение сложнополиэфирполиаминных и четвертичных сложнополиэфирполиаммонийных соединений в качестве ингибиторов коррозии
WO2005117846A3 (en) Ice inhibitors for the treatment of autoinflammatory diseases
EP2097377A4 (de) Renininhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties